Hana down on stopped Talvesta Phase II

On Tuesday, HNAB was down $0.35 to $7.18 following an annoucement late Monday that it suspended the Phase II portion of a Phase I/II trial of Talvesta talotrexin (PT-523) to treat patients with relaps...